26 November 2020
BEUC welcomes Commission fines on Teva and Cephalon for agreement to delay marketing of generic sleep drug
The European Consumer Organisation (BEUC) welcomes the European Commission’s decision today to fine Teva and Cephalon 30 and 30.5 million euros respectively for agreeing not to market a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, in Europe for six years. The “pay for delay” agreement, which the Commission has found to violate EU antitrust rules, allowed Cephalon to charge European patients and healthcare systems higher prices for the drug in the six year period before Teva finally marketed its generic alternative.
25 November 2020
The EU Commission published its Pharmaceutical Strategy today, aiming to ensure patients timely access to safe and affordable treatment and to support medical innovation and pharma competitiveness. The Strategy brings momentum to effectively address medicine shortages and high prices, a long-standing issue in the EU.
13 November 2020
Today the European Commission adopted the “Consumer Agenda”, its consumer policy strategy for the next five years. It lays down the Commission’s consumer policy objectives and will serve as guidance to include consumer interests in all policy areas. Focus areas are the green and digital transition as well as the post-COVID economic recovery.
Our work areas
As consumers are faced with a growing amount of information from different sources, we advocate for high quality and non-promotional information about health products.
The ageing of the population, rising healthcare costs and the economic crisis are challenging the sustainability of healthcare systems and consumers’ access to treatments.
Health scandals such as the weight-loss drug Mediator and the faulty PIP breast implants keep undermining consumers’ confidence in the safety of available health products and their oversight by the competent authorities.
- Ensure consumers have access to high quality healthcare in all EU Member States
- Guarantee consumers benefit from safe and innovative treatments
- Allow consumers to make informed choices regarding their health